Primary Site >> Pancreatic Cancer

Gene >> ERCC2

Journal: Invest New Drugs. 2012 Jun;30(3):1164-74.
Title: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Author: Oh, Do-Youn|Lee, Keun Wook|Lee, Kyung-Hee|Sohn, Chang-Hak|Park, Young Suk|Zang, Dae Young|Ryoo, Hun-Mo|Song, Hong-Suk|Kim, Jin-Soo|Kang, Hye-Jin|Kim, Bong-Seog|Bang, Yung-Jue
PMID: 21404106
Journal: Int J Cancer. 2013 Aug 15;133(4):1016-22.
Title: Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Author: Avan, Amir|Pacetti, Paola|Reni, Michele|Milella, Michele|Vasile, Enrico|Mambrini, Andrea|Vaccaro, Vanja|Caponi, Sara|Cereda, Stefano|Peters, Godefridus J|Cantore, Maurizio|Giovannetti, Elisa
PMID: 23390054
Journal: Int J Clin Exp Pathol. 2015 Sep 1;8(9):11579-86. eCollection 2015.
Title: Association of single nucleotide polymorphisms of DNA repair genes in NER pathway and susceptibility to pancreatic cancer.
Author: Zhao, Fuli|Shang, Yuhong|Zeng, Chen|Gao, Dongdong|Li, Ke
PMID: 26617894
Journal: Genet Mol Res. 2016 Mar 18;15(1). pii: gmr7273.
Title: Role of single nucleotide polymorphisms of DNA repair genes in susceptibility to pancreatic cancer in Chinese population.
Author: Ying, M F|Zhao, R
PMID: 27050953
Journal: Genet Mol Res. 2016 Mar 31;15(1). pii: gmr7879.
Title: Association between ERCC1 and ERCC2 gene polymorphisms and susceptibility to pancreatic cancer.
Author: He, M G|Zheng, K|Tan, D|Wang, Z X
PMID: 27051038
Journal: Oncotarget. 2017 Jul 25;8(30):50124-50132.
Title: Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis.
Author: Wu, Yang|Lu, Zi-Peng|Zhang, Jing-Jing|Liu, Dong-Fang|Shi, Guo-Dong|Zhang, Chun|Qin, Zhi-Qiang|Zhang, Jian-Zhong|He, Yuan|Wu, Peng-Fei|Miao, Yi|Jiang, Kui-Rong
PMID: 28223548